StemCell Therapy

If youre doing it right, your Thanksgiving leftovers should be gone by now (so many turkey+stuffing+gravy sandwiches!).

Evidently, preparing for Thanksgiving in the middle of a year-long pandemic was a logistical nightmare for BIG TURKEY (Butterball, Perdue, Foster Farms, etc.), thanks to labor shortages and reduced family gatherings.

This got me wondering how long it will be before we see lab-grown, cultured turkey on the tables. Sure, cultured meat still has to overcome issues around scale, affordability and widespread governmental approval. And there are some who doubt whether cultured meat will ever become a thing at all.

But as an industry sector, cultured meats march towards our dinner table continues to make gains. Just this week, Eat Just announced today that it received the worlds first regulatory approval to sell cultured chicken in Singapore. And thats just the latest development capping off what has been a robust year in the cell cultured meat space that has also featured:

And that doesnt even include the Ouroboros Steak art project that designed a kit for creating cell-based human meat. (Relax, its not real.) (We hope.)

While 2020 has been a pretty garbage year for the most part, that just hasnt been the case for cell-based meats. As you can see from the assortment of stories, lot of companies are working on the problem from a lot of different angles, and all of them are making progress.

Now, we wont be serving lab-grown turkey next year (or, presumably the year after that), but watching all these startups innovate on food tech that could help make food production more abundant and equitable is something to be thankful for.

Tetras Tiny Dishwasher (Finally) Headed to Market

Heatworks Tetra countertop dishwasher is an example of a product that I totally dont need and yet totally want.

We first covered the Tetra back at CES 2018, where we were enthralled by the diminutive dishwasher that could clean a few settings of dishes with only a half gallon of water in ten minutes. Fun!

Well, things have been quiet on the Tetra front since that CES and we were wondering if the device would ever actually make it to market. Turns out, the company was trying to solve the complex issue around soap dispensing in its machine.

This week, Heatworks announced that it has partnered with BASF to make that complicated mechanism and bring the Tetra to market. According to the press announcement, the improved Tetra will be designed to deliver custom solutions and dosing, dependent on the selected wash cycle, ensuring each cleaning cycle is optimized. Tetras cartridges will last for multiple loads and consumers will be able to sign up for a subscription, so that cartridges are shipped to them automatically.

That last part about a proprietary soap cartridge is a bit of a bummer. Were not a big fan of Keurig-style solutions that lock you into a particular ecosystem. But we are happy to see that the Tetra is still alive and expected to be available in the back half of 2021.

More Headlines

Exclusive: Blendid and Jamba Co-Brand New Smoothie Robot The robot is now open for business at a Walmart in Dixon, California. This is the first co-branded robot from Blendid and its second to open up at a Walmart.

Zuul Teams Up With Thrillist to Launch Rotating Ghost Kitchen A series of 10 different NYC restaurants will each hold a two-week residency offering exclusive delivery-only meal offerings made out of Zuuls ghost kitchen facility in Manhattans SoHo neighborhood.

The Spoons Plant-Based Egg Round-Up Plant-based eggs are poised to become the next big thing in the plant-based space, and it can be hard to keep up with all of the companies involved in this industry. Weve pulled together some of the emerging and bigger players in this space.

3D Meat Printing Startup SavorEat Goes Public The Israeli startup has had an initial public offering (IPO) on Tel Aviv Stock Exchange (TASE), raising NIS 42.6 million ($13 million) in funding.

HungryPanda Raises $70M to Provide Food Delivery to Overseas Chinese Customers The London, U.K.-based company will use the new funds to continue its global expansion, delivering authentic Chinese restaurant food and groceries to Chinese people living abroad.

Related

See the article here:
And Now, a Moment for Culture(d Meat) - The Spoon

A calorie restricted diet generally consists of eating a very low-calorie but nutritionally balanced diet that meets 100 percent of vitamin, mineral, protein and essential fat needs, according to Harvard Health.

The link between calorie restriction and longevity has been established across many species.

In a study published in Nature Communications, researchers found that monkeys who ate a 30 percent calorie restricted diet lived longer than those on a regular diet.

Six of the 20 monkeys on a calorie restricted diet have lived beyond 40 years.

READ MORE:How to live longer: Diet shown to burn fat, improve heart health and to boost longevity

However, Duke researchers mounted this hurdle by looking at measures of biological age.

In a study published earlier this year in The Journals of Gerontology: Series A, researchers divided volunteers into two groups a calorie restriction group and a regular diet group.

The calorie restriction group aimed to cut their caloric intake by 25 percent although by the end of the two-year study they had only achieved a 12 percent reduction.

After each one-year period, the biological age of people in the calorie restriction group increased by 0.11 years, compared with 0.71 years for people who stuck with their usual diets.

Researchers calculated biological age using chronological age and biomarkers for things such as cardiovascular and immune system function, total cholesterol, and haemoglobin levels.

However, researchers only followed people for two years - whether these benefits continue after this point, and at what level, is unknown.

It is unclear exactly why calorie restriction increases the lifespan of many species.

The somewhat limited evidence that does exist suggests it involves resetting the bodys biological clock.

This clock is more usefully understood as a set of genes that change activity in order to sync with the cycle of day and night.

In a recent study published in the journal Cell, researchers found that the biological clock activated different genes in liver cells of older mice, compared with younger ones. As a result, cells in older mice processed energy inefficiently.

However, when researchers cut the calorie intake for older mice by 30 percent for six months, the energy processing in the cells resembled that of young mice.

A second research group, in another study published in Cell, saw a similar reboot of the biologic clock of stem cells in older mice fed a calorie-restricted diet.

Continued here:
How to live longer: Calorie restriction may reset your biological body clock - Express

The holidays can be a particularly difficult time, especially for seniors with diabetes.

Dr. Martin Nejat, a family medicine doctor at Conviva Care Centers, has provided some insight on why its so important to stay healthy during the pandemic.

What exactly is diabetes?

Our body breaks down the food we eat into sugar or energy, stated Conviva Care Centers. The pancreas makes insulin to help push the sugar into your cells. When you have diabetes, your body either cant make enough of the insulin, or is not able to use it as well as it should.

Diabetes is a very serious condition its a complex medical problem that is very prevalent in the San Antonio area, according to Nejat.

There are four types of diabetes. In the San Antonio area, when we talk about diabetes, we are usually referring to Type 2 diabetes, Nejat said. Its a disease of basically obesity. The sugars are high because the body simultaneously has decreased insulin production and insulin resistance and both of these conditions are caused by obesity.

Is all sugar created equal?

Absolutely not. One way to monitor this is by using the glycemic index, said a representative for Conviva Care Centers.

Nejat said any organ in the body can be affected by high sugar.

Right now we are in a pandemic, and one of the ways that makes you more likely to have serious complications of COVID is poorly controlled diabetes, Nejat said.

How should I read a nutrition label to assess if this food is OK for me to eat?

You want to pay close attention to the carbohydrates, which are broken down into sugar, specifically, the added sugar.

Another rule of thumb is to do most of your grocery shopping around the perimeter of the grocery store, picking up fresh fruit and produce, meats, etc., and stay away from the packaged goods, known as processed foods.

How do I lower my blood sugar?

Take medication, have a balanced diet, drink plenty of water and exercise frequently.

If you are looking for a new health care group, Conviva Care Centers has eight locations in San Antonio -- and each location has activity centers that are free and open to anyone ages 55 and older for primary care. To learn more, click here.

Visit link:
Have diabetes? Health care group provides tips on how to manage the disease - KSAT San Antonio

A novel lower-cost noninvasive continuous glucose monitor (CGM) combined with a digital education/guidance program is set to launch in the United States and Europe this month for use in type 2 diabetes.

With the goal of improving management, or even reversing the condition, Neumara's SugarBEAT device is thought to be the world's first noninvasive CGM.

Its cost is anticipated to be far lower than traditional CGM, and it's aimed at a different patient population: those with type 2 diabetes or prediabetes who may or may not be performing fingerstick glucose monitoring, but if they are, they still aren't using the information to guide management.

"This isn't about handing out devices and letting patients get on about it on their own accord. This is really about supporting those individuals," Faz Chowdhury, MD, Nemaura's chief executive officer, told Medscape Medical News in an interview.

He pointed to studies showing improvements in glycemic control in patients with type 2 diabetes who were instructed to perform fingerstick blood glucose testing seven times a day for 3-4 days a month and given advice about how to respond to the data.

"This is well-established. We're saying we can make that process a lot more scalable and affordable and convenient for the patient...The behavior change side is digitized," Chowdhury said. "We want to provide a program to help people reverse their diabetes or at least stabilize it as much as possible."

Asked to comment, Nicholas Argento, MD, diabetes technology director at Maryland Endocrine and Diabetes, Columbia, told Medscape Medical News: "It's interesting. They're taking a very different approach. I think there's a lot of validity to what they're looking at because we have great CGMs right now, but because of the price point it's not accessible to a lot of people."

"I think they're onto something that could prove to be useful to a larger group of patients," he added.

Instead of inserting a catheter under the skin with a needle, as do current CGMs, the device comprises a small rechargeable transmitter and adhesive patch with a sensor that sits on the top of the skin, typically the upper arm. Glucose molecules are drawn out of the interstitial fluid just below the skin and into a chamber where the transmitter measures the glucose level and transmits the data every 5 minutes via Bluetooth to a smartphone app.

Despite this noninvasive approach, the device appears to be about as accurate as traditional CGMs, with comparable mean absolute relative difference (MARD) from a gold standard glucose measure of about 11%-12% with once-daily calibration versus 10%-11% for the Abbott FreeStyle Libre.

Unlike traditional CGMs, SugarBEAT is meant to be worn for only 14 hours at a timeduring the day and for 2-4 days per month rather than every day.

It's not aimed at patients with type 1 diabetes or those with type 2 diabetes who are at high risk for hypoglycemia. It requires once-daily fingerstick calibration and is not indicated to replace fingersticks for treatment decisions.

SugarBEAT received a CE Mark in Europe as a Class IIb medical device in May 2019. That version provides real-time glucose values visible to the wearer. In the United States the company submitted a premarketing approval application for the device to the Food and Drug Administration (FDA) in July 2020, which awaits a decision.

However, FDA is allowing it to enter the US market as a "wellness" device that won't deliver real-time values for now but instead will generate retroactive reports available to the physician and the patient.

And last month, UK-based Neumara launched the BEATdiabetes site, which allows users to sign in and link to the device once it becomes available.

The site provides "scientifically validated, personalized coaching" based on a program developed at the Joslin Diabetes Clinic, and will ultimately include monitoring of other cardiovascular risk factors with digital connectivity to a variety of wearables.

"Fingerstick monitoring for type 2 diabetes is only so useful," Argento told Medscape Medical News.

"It's difficult to get people to monitor in a meaningful way." If patients perform them only in the morning or at other sporadic times of the day, he said, "Then you get a one-dimensional picture...and they don't know what to do with the information anyway, so they stop doing it."

In contrast, with SugarBEAT and BEATDiabetes, "I think it does address a need that fingerstick monitoring doesn't."

Argento did express a few caveats about the device, however. For one, it still requires one fingerstick a day for calibration. "If people don't like needles, that might be a disincentive."

Also, despite the apparently comparable MARD to that of conventional CGMs, that measure can still "hide" values that may be consistently either above or below target range.

"MARD is like A1c in that it's useful but limited...It doesn't tell you about variability or systemic bias."

Argento also said that he'd like to see data on the lag time between the interstitial fluid and blood glucose measures with this noninvasive method as compared to that of a subcutaneous catheter.

However, he acknowledged that these potentials for error would be less important for patients with type 2 diabetes who aren't generally taking medications that increase their risk for hypoglycemia.

In all, he said, "Stay tuned. I think this is part of a movement going away from point-in-time to looking at trends and wearables and data to enrich decision-makingThere are still some unanswered questions I have but I think they're onto a concept that's useful for a broader population."

Chowdhury is an employee of Neumara. Argento consults for Senseonics and Dexcom, and is also a speaker for Dexcom.

For more diabetes and endocrinology news, follow us on Twitter and Facebook.

Read the original post:
Noninvasive, Low Cost CGM for Type 2 Diabetes Coming in US and EU - Medscape

November was National Diabetes Month. WJZs Nicole Baker spoke with LifeBridge Health Dr. Asha Thomas about what diabetes is and how to prevent getting at least one form of it.

Thomas, who is the Division Head of Endocrinology & Metabolism and Vice Chair of the Department of Medicine at Sinai Hospital, answered questions about diabetes prevention and treatment.

You can watch the full interview above. Heres some of the Q&A:

Nicole Baker: So we know that you work in Endocrinology and Metabolism at Sinai, which means you really know how diabetes works, but for people who may not specifically know about diabetes explain in simple terms, what it is.

Dr. Asha Thomas: Absolutely, in terms of diabetes, a word we hear a lot, I think automatically when we hear the word, we think of sugar and blood sugar and all of this. But in general, diabetes is a disorder where there is a mismatch between how our body handles carbohydrates and sugars. And how insulin works in our bodies, and you know there are different types of diabetes which we can talk about, but in essence, that is really the issue. Its just our bodys inability to kind of manage and handle our sugars or carbohydrates.

NB: What are some of the habits lifestyle changes folks can make if they are prediabetic or is it too late at that point?

Dr. Thomas: That is the population, honestly that for myself, Im most excited to try to capture because there are certain things that are actually pretty low tech and not very expensive that are very, very effective. So primarily diet, exercise and weight, either at least even maintenance or weight loss. So if we capture folks in that range, were really able to prevent diabetes.

The other thing to talk about that I think is very important is whos at risk for this. So its a whole host of people these are people who have a strong family history of diabetes. Folks, particularly women, whove had gestational diabetes or diabetes during a pregnancy. They have a higher risk of developing diabetes later on. Different ethnic groups have a higher risk of diabetes including African American, Hispanic, Asian Americans, Native Americans. Then obviously young people, children who are overweight during their youth and teen years as another high risk group, so if we can target that and really work with them early big benefits later on.

NB: What is the difference between Type 1 Diabetes and Type 2 Diabetes? People may not know how they differ.

Dr. Thomas: Thats actually a distinction thats becoming more and more complicated. But generally Type 1 Diabetes is a disorder. That is an autoimmune problem, where our bodys pancreas is really getting sort of damaged from an autoimmune process, such that we just dont make enough insulin. Traditionally, we think of it as younger people who get it, that they may develop it, you know when theyre young sort of between 4 and 6. And then theres another sort of peak like in the early teen years where they present and many times they present, theyre not feeling well and they need insulin from the beginning.

Type 2 Diabetes is more traditional, what we think of like a more of an adult who presents with diabetes with an abnormal blood test. It can be because they had issues with weight loss, fatigue, blurred vision, going to the bathroom a lot to urinate and feeling really thirsty. Generally those are folks that are diagnosed and they can be managed either with pills or with insulin, depending on how far along. Sometimes its not that easy to tell between the two and there are different genetic components of each one as well.

Visit link:
Ask A Doc: Everything You Need To Know About Diabetes - CBS Baltimore

A growing body of research suggests that people with diabetes are more likely than others to develop severe COVID-19. Those with difficulty managing their diabetes may be at particularly high risk.

In a study published earlier this month, researchers from Kings College London in the United Kingdom evaluated patients with diabetes who had been admitted to the hospital for COVID-19.

They found that patients who had a complication known as diabetic retinopathy were more likely than other patients with diabetes to develop severe breathing problems from COVID-19.

Patients with diabetic retinopathy were five times more likely than other patients with diabetes to be intubated and put on a ventilator to help them breathe.

This is the first time that retinopathy has been linked to severe COVID-19 in people with diabetes, lead author of the study, Dr. Antonella Corcillo, said in a press release.

Retinopathy is a marker of damage to the blood vessels, and our results suggest that such preexisting damage to blood vessels may result in a more severe COVID-19 infection requiring intensive care treatment, she added.

Diabetic retinopathy is a type of eye disease that develops when small blood vessels in the eye are damaged. Its one of many potential complications of type 1 and type 2 diabetes.

Diabetic retinopathy itself may not cause more severe COVID-19. Rather, its possible that the underlying blood vessel damage that causes retinopathy also contributes to an increased risk of complications from COVID-19.

Over time, high blood sugar levels in people with diabetes can damage blood vessels in not only the eye but also other parts of the body.

Preexisting blood vessel damage may put people with COVID-19 at heightened risk of complications from the infection.

Dr. Mangala Narasimhan, SVP, director of critical care services at Northwell Health in New Hyde Park, New York, told Healthline that developing diabetic retinopathy may indicate that diabetes is affecting a persons overall health.

We know people with more comorbidities do worse with COVID, so this study would be consistent with that overall theme, Narasimhan said.

The Centers for Disease Control and Prevention (CDC) warns that people with type 2 diabetes are at heightened risk of severe illness from COVID-19. Those with type 1 or gestational diabetes might also be at increased risk.

To protect their health, its important for people with diabetes to manage their blood sugar levels and other risk factors including blood pressure, blood cholesterol, and weight.

This can help reduce the chances of developing complications from diabetes, including blood vessel damage. It may also lower their risk of developing severe COVID-19 if they contract the novel coronavirus.

Gaining control of [unmanaged] diabetes can be a daunting task, but its important for patients to remember that even small efforts can result in significant improvement and therefore a reduction in risk of complications from COVID-19, Dr. Minisha Sood, an endocrinologist at Lenox Hill Hospital in New York City, told Healthline.

To maintain healthy blood sugar levels, blood pressure, cholesterol, and weight, practicing healthy habits is key. Its also important for people with diabetes to schedule regular health checkups and follow their doctors recommendations for blood sugar testing, said Narasimhan.

Regular physician follow up, ophthalmology follow up, and control of diet and exercise, along with social distancing and mask wearing, are the best steps you can take to prevent severe COVID infection, Narasimhan advises.

The more you manage your diabetes, the better you will do with COVID, she added.

Read more from the original source:
The Link Between Diabetes and Severe COVID-19 - Healthline

The impact Covid-19 has had on people with chronic conditions has been dramatic. Among those younger than 65 who died from the virus, 20% had diabetes, according to data from the U.S. Centers for Disease Control and Prevention, based on data collected through November 14.

The virus poses myriad challenges for people struggling with Type 2 diabetes, which requires constant, long-term management. But the stress caused by Covid-19s impact on the economy, and indirectly by the CDC guidance to reduce risk of contracting Covid-19 by social distancing, can also cause depression, which many people with chronic conditions struggle with as it is.

More than 200 healthcare professionals from 47 countries have ranked diabetes as the condition that will be most impacted by the reduction in healthcare resources due to Covid-19, according to a new report from Omada Health: 5 reasons why Covid-19 makes digital diabetes treatment critical.

The public health crisis drives home the need for diabetes management programs with an effectiveness that can help vulnerable people weather this trying time.

The rapid scaling up of telehealth options by hospitals to reduce the number of people coming to the hospital has been a significant development that could be a great source of comfort long after the virus is no longer a public health crisis. And yet, gaps remain in telehealth services.

Covid-19 has made the need for personalized care even more important. Its critical that people with diabetes have access to support that fits their lifestyle, and is accessible when they need it most, according to the Omada Health report.

Omada for Diabetes program participants achieved meaningful outcomes four months after beginning the program, even prior to the inclusion of continuous glucose monitoring (CGM), according to a new study conducted between November 2019 and July 2020. Four months after beginning the program, participants decreased total cholesterol by 39 points on average for people with high cholesterol.

All study participants also reduced average Hemoglobin A1c by 0.8 percent, including a 1.4 percent average reduction for individuals with starting values at or above 9 percent.

To learn more about the impact of Covid-19 on people with diabetes and the Omada for Diabetes program, Fill in the form below to download 5 reasons why Covid-19 makes digital diabetes treatment critical.

Photo: NicoElNino, Getty Images

Excerpt from:
Covid-19's terrible toll on diabetes patients. What can be done? - MedCity News

Author Irene Richardson - November 30, 2020November 30, 2020Exercise is an important step in preventing type 2 diabetes. Photo via Blue Cross and Blue Shield of Alabama (photo taken in 2019)

As we close out National Diabetes Awareness month, its important to remind ourselves of the risks attached to diabetes. By changing a few habits, you can prevent type 2 diabetes and manage it. We caught up with Blue Cross and Blue Shield of Alabamas senior medical director, Dr. Anne Schmidt, to learn what resources are available.

One of the things that always stands out to me is when you look at national statistics from the CDC, they state if we changed diet and activity level along with peoples use of tobacco we could prevent 80% of type 2 diabetes.

You read that right80%. A 2019 report from the CDC states that from the over 34 million Americans who have diabetes, approximately 90-95% of them have type 2 diabetes. Lets look at how we can lower this statistic.

Diabetes isnt just about blood sugar. It affects kidney health and can cause higher rates of kidney failure and dialysis. Diabetes also affects blood sugar and how your body metabolizes fat. There are all kinds of different impacts of diabetes beyond just blood sugar. So, thats why its really important we help patients manage that.

Most people look at any lifestyle change as a daunting task. Even getting up 10 minutes earlier than your normal routine can prove difficult.

Its true that redirecting daily habits isnt always as easy as it appears on the surface. But, in order to prevent type 2 diabetes, these modifications wont require a complete overhaul of your life.

Incorporate changes into your daily life. We know if you lose 5-7% of your body weight and get 150 minutes of physical activity a week, it can make significant improvements.

This might look like finding ways to add in an extra green vegetable at lunch and dinnertime as you begin to develop new healthier habits.

In terms of exercise, its the same deal. You hear it over and over for a reasonuse the stairs, park a little further away, walk around the block on your lunch break.

When it comes to 20 minutes of exercise a day versus kidney disease, Ill side with the former. We even rounded up 19 trails in Birmingham you can enjoy while also staying socially distanced.

A common myth Dr. Schmidt says people tend to believe is that if diabetes runs in your family, youre doomed. Too often, people give up trying to prevent type 2 diabetes with the notion that their fate is already crystal clear.

Even if you already have type 1 or type 2 diabetes, its not unrealistic to manage it and live a comfortable life.

Its possible to manage diabetes. Some people who have relatives with diabetes might have a fatalistic attitude of, I might as well give up because Im going to end up like my aunt or dad or grandfather.'

While you cant prevent type 1 diabetes, BCBSAL has great resources like lifestyle management programs for living with type 1 diagnosis that well talk about later. Type 2 diabetes, on the other hand, is avoidable. Prevention practices should take place as early as possible.

We are seeing Type 2 diabetes in elementary school-aged children now. Its never too young to start thinking about preventing the diagnosis.

Its really about exercise, in addition to your diet. Exercise changes the way your body processes the sugar that you eat.

Whether youre hoping to prevent diabetes or looking to navigate your condition, BCBSAL has many valuable resources for its members including myBlueWellness. This program provides important information about making better choices when it comes to managing habits and becoming compliant with a treatment plan.

BCBSAL offers chronic condition coaching programs. Type 2 diabetes is one of the diagnoses most prevalent in our state. We use clinical guidelines and offer educational materials and self-management support strategies for members.

If you have type 1 or type 2 diabetes, BCBSAL ensures youre on the best track to managing it.

If you manage your diabetes well, you can live a long and healthy life. BCBSAL can definitely help through diabetes prevention programs and chronic condition coaching. We also have lifestyle management programs.

Its also imperative you maintain routine doctors visits. If youre not comfortable heading into the doc right now, take advantage of BCBSALs telehealth services.

Related

Visit link:
Prevent type 2 diabetes with 5 tips from Blue Cross and Blue Shield of Alabama - Bham Now

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center.

Risk of intubation for COVID-19 in very sick hospitalized patients was increased over fivefold in those with diabetic retinopathy compared to those without, in a small single-center study from the UK.

Importantly, the risk of intubation was independent of conventional risk factors for poor COVID-19 outcomes.

"People with pre-existing diabetes-related vascular damage, such as retinopathy, might be predisposed to a more severe form of COVID-19 requiring ventilation in the intensive therapy unit," said lead investigator Janaka Karalliedde, MBBS, PhD.

Karalliedde and his colleagues note that this is "the first description of diabetic retinopathy as a potential risk factor for poor COVID-19 outcomes."

"For this reason, looking for the presence or history of retinopathy or other vascular complications of diabetes may help health care professionals identify patients at high risk of severe COVID-19," added Karalliedde, of Guy's and St Thomas' NHS Foundation Trust, London, UK.

The study was published online in Diabetes Research and Clinical Practice.

The prevalence of diabetic retinopathy is thought to be around 55% in people with type 1 diabetes and 30% in people with type 2 diabetes, on average.

Karalliedde is part of a research group at King's College London that has been focused on how vascular disease may predispose to more severe COVID-19.

"COVID-19 affects the blood vessels all over the body," he said, so they wondered whetherhaving pre-existing retinopathy "would predispose to a severe manifestation of COVID-19."

The observational study included 187 patients with diabetes (179 patients with type 2 diabetes and eight patients with type 1 diabetes)hospitalized with COVID-19 at Guy's and St Thomas' NHS Foundation Trust between March 12 to April 7 (the peak of the first wave of the pandemic in the UK).

"It was an ethnically diverse population who were very sick and provides a clinical observation of real life," Karalliedde said.

Nearly half of patients were African Caribbean (44%), 39% were White, and 17% were of other ethnicities, including 8% who were Asian. The mean age of the cohort was 68 years (range, 22-97 years), and 60% were men.

Diabetic retinopathy was reported in 67 (36%) patients, of whom 80% had background retinopathy and 20% had more advanced retinopathy.

They then looked at whether the presence of retinopathy was associated with a more severe manifestation of COVID-19 as defined by the need for tracheal intubation.

Of the 187 patients, 26% were intubated and 45% of these patients had diabetic retinopathy.

The analysis showed those with diabetic retinopathy had an over fivefold increased risk for intubation (OR, 5.81; 95% CI, 1.37 - 24.66).

IOf the entire cohort, 32% of patients died, although no association was observed between retinopathy and mortality.

"A greater number of diabetes patients with COVID-19 ended up on the intensive therapy unit. Upon multivariate analysis, we found retinopathy was independently associated with ending up on the intensive therapy unit," stressed Karalliedde.

However, they note that "Due to the cross-sectional design of our study, we cannot prove causality [between retinopathy and intubation]."

"Further studies are required to understand the mechanisms that explain the associations between retinopathy and other indices of microangiopathy with severe COVID-19."

Diabetes Res Clin Pract. Published online November 2, 2020. Full text

For more diabetes and endocrinology news, follow us on Twitter and Facebook.

Read more:
Diabetic Retinopathy May Predict Greater Risk of COVID-19 Severity - Medscape

Following authorization allowing pharmacists to administer childhood vaccines, some pediatricians have expressed concerns that this deprives children of medical care or could lead to missed vaccines.

The researchers launched the Perinatal Experiences and COVID-19 Effects Study to better understand the mental health and well-being of pregnant and postpartum individuals within the United States during the COVID-19 pandemic.

Despite the COVID-19 pandemic, several promising drugs are expected to hit the market in late 2020 and early 2021.

Beta-blockers could be used as a potential treatment for COVID-19, according to a study by Italian and Australian researchers.

Patients with relapsed/refractory leukemia and lymphomas generally have a grim prognosis, which has paved the way for immunotherapy treatments.

Researchers find no clear therapeutic benefit of intravenous immunoglobulin for the prevention of postnatal relapses of multiple sclerosis.

Further, the findings suggest that cancer survivors are also likely to be at an increased risk of severe coronavirus disease 2019 (COVID-19) outcomes, given that both influenza and COVID-19 are both epidemic respiratory viruses.

Four case studies demonstrate common OTC treatments for cough.

Compared with patients with focal epilepsy, those with genialized epilepsy have a higher risk of obstructive sleep apnea.

FDA grants fast track designation to irinotecan liposome injection (Onivyde; MM-398) as second-line monotherapy for patients with small cell lung cancer whose disease progressed following a platinum-based chemotherapy regimen.

Warning letters requested that companies immediately stop selling these unapproved products and said consumers concerned about COVID-19 should talk to their health care provider.

View original post here:
People With Type 2 Diabetes Have a Greater Risk of Cardiovascular Disease Even With Risk Factors Optimally Controlled - Pharmacy Times

Newswise EL PASO, Texas November is National Diabetes Month, a time when the nation comes together to shed light on one of the leading causes of death and disability among U.S. citizens. The University of Texas at El Paso (UTEP) is joining the fight against the disease through innovative research made possible through a recent $1.2 million grant by the National Institutes of Health (NIH) to advance understanding of a critical diabetic heart condition.

The project will use 3D bioprinting to better understand how type 2 diabetes progresses inside the human body. The research team will re-create cardiac tissue, made up of human cardiac cells from both diabetic and healthy donors, to form a heart model closely resembling actual heart tissue found inside the human body with an electrical rhythm that can contract, relax and function as a human heart would.

Binata Joddar, Ph.D., associate professor of biomedical engineering in the metallurgy, materials and biomedical engineering department at UTEP, is leading the cutting-edge research.

We are going to compare how the progression of diabetes is affecting the functions of healthy and diabetic cells and tissue, Joddar said. We are going to study the effect of diabetes progression and how it affects the normal electrical rhythm of the heart when diabetes is advancing in these cells and how it impacts the individual behavior of the cells.

Joddars research will focus on cardiomyopathy, a heart condition often experienced by patients with type 2 diabetes, where the heart wall remodels itself and can become either thinner or thicker and affect the hearts ability to pump blood and properly oxygenate the body. This condition often leads to catastrophic outcomes for patients such as heart failure and death.

Cardiomyopathy is a huge problem for type 2 diabetes patients, Joddar said. There is a lack of targeted treatment for this condition. It can only be diagnosed by clinicians, and once diagnosed, there is only symptom management available with no real cure.

Once Joddar and her team of student researchers successfully creates the cardiac tissue model, they also will be able to use it for cardiac toxicity screening to see how certain common drugs approved by the U.S. Food and Drug Administration impact the heart.

Patients with diabetes, cancer and other diseases typically take a lot of drugs to treat their symptoms, but often a little of the dose gets mixed in the bloodstream and circulates through the heart muscle and is toxic to cardiac tissue. The cardiac model we create can be used to screen the toxicity of certain common drugs, Joddar said.

The project will expose UTEP students to bioengineering research and provide hands-on experience to empower the next generation of scientists and engineers to advance diabetes research and awareness.

Dr. Joddars research is both innovative and impactful, said Patricia Nava, Ph.D., dean of UTEPs College of Engineering. We are proud to have the facilities and capacity for her to carry out her comparative studies of diabetic and healthy cardiac tissue and changes invoked by medication, as this is sure to shed light not only on basic research, but also clinical treatment of patients. This innovative research is important to the community and global population of diabetes patients and will be a prime opportunity for UTEP engineering students to contribute to impactful, life-changing research.

The University of Texas at El Paso is one of the largest and most successful Hispanic-serving institutions in the country, with a student body that is 83% Hispanic. It enrolls nearly 25,000 students in 166 bachelors, masters and doctoral programs in 10 colleges and schools. With more than $100 million in total annual research expenditures, UTEP is ranked in the top 5% of research institutions nationally and fifth in Texas for federal research expenditures at public universities.

See original here:
UTEP Awarded $1.2 Million by NIH to Advance Research on Diabetes-Related Cardiac Complications - Newswise

Last of 3 parts

By Maridith YahlNKyTribune reporter

Embedded within St. Elizabeth Physicians in Covington, The Regional Diabetes Center (RDC) offers the only diabetes education classes in Northern Kentucky.

The RDC sees anyone having a physicians referral, says Kate Moser, MSN, RN, CDCES, Diabetes Education Quality Coordinator. American Diabetes Association (ADA) Education-Certified Diabetes Program, the RDC provides diabetic and endocrinology care.

Kate Moser

There are so many decisions, every single day, that someone with diabetes has to make and it can be really overwhelming, says Moser.

The center works with patients who have type 1 or type 2 diabetes, and diabetes during pregnancy, which is somewhat different than gestational diabetes, she says.

It is hard for newly diagnosed patients to know where to start or the types of changes needed.

We like to be their first touchpoint, getting them educated, giving them the tools, they need, says Moser. Individual appointments or group classes are available.

We run the gamut from someone who has pre-diabetes or is newly diagnosed with type 2, through someone looking for the most advanced technology, Moser says.

Comprehensive diabetes classes are taught in groups by a Registered Nurse (RN) and Registered Dietitian (RDN). Healthy eating, medication, healthy coping, exercise, healthy problem solving are some topics discussed.

Registered Dietitians offer Medical Nutrition Therapy (MNT). In a one-on-one meeting, the RDN works with the client on what the client wants to focus on.

Meal planning, thats the number one question we get asked is, what can I eat? but it is wildly important, Moser says.

The RDC is creating a program for those diagnosed with prediabetes. It will be a series of workshops in which clients can pick and choose the topics from which they will benefit the most. Realizing most insurances do not cover this education, Moser plans to make it low-cost.

Receiving their five-year recertification in January from the ADA, the RDC, Moser says, has someone to talk to about anything. There is an exercise physiologist on the staff, four registered dietitians, six registered nurses, of which eight are Certified Diabetes Care Education Specialists (CDCES). The CDCES certification requires an exam and the RN must have taught about living with diabetes over 1000 hours.

Anyone that you meet within our team is going to be very seasoned and have experience with all different types of people, from all different places in life, with different kinds of concerns and needs, Moser says.

Plan your meals carefully.

We want people to know they can reach out anytime they have a change in their circumstance. We really want to be there to support people in the community, to give them information and resources, and make sure that they know what to say to their provider, financial issues, or emotional distress issues, depression, and chronic disease. Those things are certainly linked to diabetes and we want to make sure that they know it is okay to reach out.

They get a lot of phone calls from those who are uninsured and want to know their options. Moser keeps up on local resources.

I always encourage them to check with their insurance provider because a lot of them do cover dietitian services for prediabetes, Moser says. Im always saying, I cant imagine its not going to change soon just because the medical costs are two to three times more.

But Moser knows cost can be a huge barrier for education, so she can direct them to other resources, like the Northern Kentucky Diabetes Coalition, for support groups and resources.

The Kentucky Diabetes Coalition has a resource finder on their website. Search by county to find diabetes classes and support groups near you.

Being able to build a good, trusting relationship with her clients is one thing Moser loves about her job. Being able to coordinate all those pieces and really meet somebody where we are spending the time talking to them about all of the daily decisions and things that impact their life is really nice, Moser says. It stems from just the basic desire to help people, but theres just something about supporting someone with what can be such a ravaging chronic disease.

Things have changed so much in this field. Thankfully, were just getting better and better but, I think that just maintaining that relationship with your education team can be really important, Moser says.

Link:
Diabetes: Regional Diabetes Center offers education classes so clients can learn to live with the disease - User-generated content

Our virtualMedCity INVEST Precision Medicine conference, December 9-11, will highlight aspects of precision medicine from the biopharma companies developing cell and gene therapies to diagnostics and the data sharing initiatives to support precision and personalized medicine.

One vexing part of any conversation on precision medicine and breakthrough therapies that have been developed and are continuing to work their way through clinical trials for cancer to rare disease is how to address the practical challenge of their high price tags. Although there are several models to cover the cost of these therapies such as Cignas Embarc Benefit Protection program,what happens when someone changes insurers when they change their job? What is fair for patients and whats fair for companies? When do these conversations even start?

The panel, Reimbursement Models for Cell and Gene Therapies, will highlight some of the pros and cons of different models that are coming to market. Panelists include Laura Okpala, Director, Reimbursement Policy, Gilead Sciences, and Mark Trusheim, Strategic Director, NEWDIGS initiative at the MIT Center for Biomedical Innovation.

Heres a preview of some of the sessions. Click here to see the agenda.

Interoperability Progress Report

How far have we progressed with sharing patient medical records? Patient data is key in unlocking riddles of medical science but interoperability is necessary to facilitate this. What companies are making an impact on a regional and national scale? What milestones are on the horizon? What obstacles continue to vex further advancement? How can we make medical records more accessible to patients?

Moderator: Elise Reuter, Senior Reporter, MedCity NewsSpeakers:Kevin Chaney, Senior Program Manager, Office of the National Coordinator for Health ITIda Sim, M.D., Ph.D., Professor of Medicine, University of California, San FranciscoNiko Skievaski, Co-Founder and President, Redox

What It Takes To Build A Successful, Regional BioInnovation HubPhiladelphia is one of many cities seeking to support the continued growth of cell and gene therapy and connected health industries. What do cities need to do to address education, training and other needs to support these sectors? This session will be held as part ofVenture Cafe Philadelphia.

(sponsored by IBX)

Lisa Dalton, Chief People Officer,Spark TherapeuticsAudrey Greenberg, Executive Managing Director,The Discovery LabsTiffany Wilson, President & CEO,University City Science Center

Moderator:Michelle Histand, Director of Innovation, Independence Blue Cross

Register nowand be part of the conversation at INVEST Precision Medicine.

More here:
Navigating the challenge of covering breakthrough therapies at MedCity INVEST Precision Medicine - MedCity News

This article is part of an op-ed series on engineering fields that will change the world byRutgers School of Engineeringfaculty.

By Umer Hassan

Real-world innovations from submarines to self-driving cars come straight from imaginary worlds of science fiction. Think Star Treks handheld tricorder, a medical diagnostic device that made its first appearance in the original TV series. This sci-fi precursor is now changing the face of personalized medicine by taking the tricorder concept to the next level.

Today, diabetics can anticipate a biosensor able to monitor their glucose levels through perspiration. A biosensor implant could detect genetic mutations as they happen, while British researchers are developing a wearable biosensor that will collect data and assess the efficacy of rehabilitation equipment and exercise.

Other biosensors will be able to quickly and inexpensively detect costly and potentially fatal medical conditions such as sepsis and AIDS. Together with Rutgers University colleagues, clinical and industry partners, my lab has been working to solve these global health challenges with new tools that focus on a highly personalized approach to medicine. Since the COVID-19 pandemic began, we are also hoping to apply this technology to fight the coronavirus.

Sepsis the bodys life-threatening response to infection is not only deadly, it is the most expensive inpatient medical condition in the United States, with patients who develop sepsis often spending days in intensive care units at a cost of $10,000 a day or more. Recognizing that sepsis is responsible for as many as 6 million largely preventable deaths a year, the World Health Organization has identified the prevention, diagnosis and management of sepsis as a pressing global health priority.

By applying electrical and computer engineering skills to identify new biomarkers and devise machine-learning algorithms, or artificial intelligence systems, we hope to dramatically improve clinicians' abilities to diagnose, predict and ultimately manage sepsis. Simply reacting to diseases is no longer enough we need to predict them in order to treat patients in a much smarter way.

To this end, we are building an inexpensive medical device that even minimally trained health care providers can use to accurately diagnosis sepsis. This automated device would cost less than $10 a test and be simple to operate not only in resource-limited settings but anywhere where a rapidly confirmed diagnosis of sepsis is needed.

In sub-Saharan Africa, where only one person in eight is even tested for HIV, many of those infected go undetected until they develop severe complications from the disease. In the near future, cheap, disposable biosensors that are as easy and convenient to use as a home pregnancy test, will detect infections with people living with HIV/AIDS in underdeveloped sub-Saharan African nations. A secondary goal is to develop sensors able to monitor a patients response to the antiretroviral therapy they receive.

The positive health and economic impact of such sensors would be felt not only in underdeveloped nations, but also in the United States by reducing the cost of a single HIV test from hundreds of dollars to as little as $10.

A smartphone-based microscope setup, working with a Galaxy S9+ attached to a 3D printed platform will display an image of white blood cells.

My lab has also made the fight against COVID-19 a priority and a natural extension of our existing work. We are seeking to develop a sensor that could measure the ability of white blood cells to kill the virus in high-risk human patients. This could lead to new therapeutic interventions and could help develop a rapid, easy-to-use widespread stratification test.

In terms of predicting health outcomes and personalizing therapeutic approaches economically, we are also collaborating with Robert Wood Johnson Medical Hospital to do just that by combining sensor data and electronic medical records data.

Advancing personalized medicine and health monitoring is also a key concern of my Rutgers School of Engineering colleague, electrical and computer engineering associate professor Mehdi Javanmard. His lab has been developing a lab on a chip with the potential to monitor everything from health to germs to pollutants.

His teams innovative biosensor could be used in hand-held devices akin to that old Star Trek tricorder or wearable devices that measure biomarkers to track your health and exposure to harmful bacteria, viruses, and pollutants.

While a single biomarker is measured in home pregnancy tests, multiple biomarkers need to be tracked simultaneously to diagnose and manage complex health conditions such as heart disease, cancer, and inflammatory diseases. The lab on a chip is designed to meet that challenge. Additionally, within the next three to five years, a lab on a chip could quickly analyze a sample of what if any harmful bacteria are on a doorknob of a bathroom; test a salad for the presence of E. coli or Salmonella bacteria; or even quickly test for the flu.

In time, a future version of the smartphone will be the true tricorder of tomorrow. Smartphone-based health sensors will ultimately transform the smartphone into an intelligent, all-in-one monitoring and diagnostic device.

Umer Hassan, an assistant professor of electrical and computer engineering at Rutgers University School of Engineering, holds a joint appointment at Rutgers Global Health Institute.

Our journalism needs your support. Please subscribe today to NJ.com.

Heres how to submit an op-ed or Letter to the Editor. Bookmark NJ.com/Opinion. Follow us on Twitter @NJ_Opinion and on Facebook at NJ.com Opinion. Get the latest news updates right in your inbox. Subscribe to NJ.coms newsletters.

See original here:
Star Trek-inspired personalized medicine is on the horizon | Opinion - NJ.com

Ibex Medical Analytics, a company in artificial intelligence (AI)-based cancer diagnostics and Institut Curie, Frances leading cancer center, today announced a research partnership aimed at improving diagnosis of breast cancer with AI.

Breast cancer is the most common malignant disease in women worldwide, with over 2 million new cases each year. As such, accurate and timely diagnosis of breast cancer is instrumental in guiding treatment decisions and improving patient survival rates. Analysis of breast tissue samples by a pathologist, typically using gross exam followed by examination under a microscope of tissue sections from biopsies or surgical specimens, remains the standard method of diagnosing and staging cancer. However, in recent years, an increase in cancer prevalence, coupled with a decline in the number of pathologists specialized in diagnosing cancer, has resulted in greater workloads and relatively long wait times for test results. Clearly, there is a growing need for automated solutions and decision support tools that can help pathologists diagnose cancer to the utmost accuracy more rapidly, while enabling comprehensive and affordable quality control.

This research partnership, the first of its kind, will include a rich dataset of breast biopsy slides, digitized using a digital pathology scanner, and analyzed for cancer detection by Ibexs Galen Breast solution. Independently, multiple pathologists from Institut Curie will diagnose the slides, followed by blinded analysis of the AI-solutions performance. Galen Breast, the first AI solution used for detection of breast cancer in pathology, was developed utilizing state-of-the-art AI and machine learning techniques, and trained on hundreds of thousands of image samples. The solution is already deployed at the pathology institute of Maccabi Healthcare Services, Israels second largest HMO, where it is used as a second read application.

The importance of breast pathology is ever increasing, as new and more personalized treatments for breast cancer become available, many of which are based on precision medicine and require more tests and diagnosis by pathologists, said Dr. Anne Vincent-Salomon, Director of Pathology at Institut Curie and the principal investigator in the study. We believe that artificial intelligence can help us meet these challenges, and we are delighted to partner with Ibex, the leader in AI for cancer diagnosis in pathology. This collaboration will enable our pathologists to experience AI firsthand and evaluate its utility for diagnosing breast cancer.

We are excited to partner with Institut Curie, a global leader in research and treatment of breast cancer, for the first-ever blinded and independent evaluation of an AI-solution for breast cancer detection, said Daphna Laifenfeld, PhD, Chief Scientific Officer at Ibex Medical Analytics. Our Galen Prostate solution has demonstrated outstanding clinical outcomes and empowers pathologists worldwide to improve diagnostic accuracy and implement 100% quality control. We are continuing to expand our platform to new tissue types, focusing this time on breast biopsies, and are thrilled to work with Dr. Vincent-Salomon and her world-leading team on this important breast cancer study.

"This collaboration illustrates Institut Curie's approach to partnership-based research, combining the expertise of clinicians with the know-how of an innovation-driven technology company, added Amaury Martin, PhD, Head of Technology Transfer and Industrial Partnerships Office at Institut Curie and Head of Carnot Curie Cancer. It illustrates our commitment to play a major role in the development of artificial intelligence approaches applied to personalized medicine.

More:
Ibex Medical Analytics and Institut Curie Partner to Improve AI-Powered Breast Cancer Detection - Technology Networks

Metabolites, the small non-polymeric molecules, which are the intermediate or final products of metabolic reactions, have emerged as powerful tools for biomedical research and precision medicine.The term metabolome, introduced in 1998, represents the whole entity of metabolites within a cell, tissue or entire organism.1Since then, metabolomics has gained impressive traction, especially due to its relevance in systems biology or the holistic approach of deciphering the complexity of biological processes. Metabolomics fits perfectly in that concept, with its strategic position downstream of genomics and transcriptomics in the omics cascade and also tightly connected and influenced by the surrounding environmental factors. Often, the metabolome provides insights where genomic profiling fails to explain a given phenotype, and for this, the field is gaining appreciation from a plethora of pathology-related areas, including cancer, diabetes and cardiac disease.2From a technical point of view, metabolite profiling relies on the principles of analytical chemistry. The main methods are mass spectrometry (ms), applied in a targeted or untargeted manner, nuclear magnetic resonance (NMR) and stable isotope labeling for matabolomic flux analysis. Each of these methods has its pros and cons and the choice depends on the study's final goals. 3, 4The diverse nature of the metabolome continually challenges researchers and creates a colorful array of opinions on which is the most comprehensive and precise approach.

"That's kind of the way targeted metabolomics is. You're looking for certain molecules, but you're only looking under the lights. And if it turns out that this is where you've lost your keys, then it works extremely well." Patti says. Nevertheless, the scientist highly appreciates the significance of targeted metabolomics: "Targeted metabolomics is extremely useful in the clinical arena and other areas of biology," but also acknowledges the importance of identifying novel metabolites and making new discoveries. "The advantage of untargeted metabolomics is the potential for discovering molecules or metabolites that are altered in a particular disease state or physiological condition that are not expected."

Patti's lab leverages on identifying new metabolites using untargeted metabolomics and he is no stranger to the obstacles this approach offers and how it differs from the targeted analysis. "When you do untargeted metabolomics, you don't know what you're looking for. The metabolic spaces are pretty ambiguous, and we can't optimize methods in the classical way that you would do in a targeted experiment," he reflects.

Newgard has a clear vision for the future and the potential of his method: "Where I see us going is always to have that strong foundation of targeted and quantitatively reproducible and rigorous profiling, but then link it to what's happening in metabolic pathways, through the ability to do metabolic flux analysis.

Although somewhat divided into their approaches and tools, metabolomics researchers are unified by their vision for a metabolomics-based approach to personalized medicine in the future, and by the common challenges they encounter and recognize. Their collective efforts will undoubtedly pave the way for deciphering the code of metabolomics.References:

1. Oliver S. Systematic functional analysis of the yeast genome. Trends Biotechnol. 1998;16(9):373-378. doi:10.1016/S0167-7799(98)01214-1.

2. Newgard CB. Metabolomics and Metabolic Diseases: Where Do We Stand? Cell Metab. 2017;25(1):43-56. doi:10.1016/j.cmet.2016.09.018.

3. Zamboni N, Saghatelian A, Patti GJ. Defining the Metabolome: Size, Flux, and Regulation. Mol Cell. 2015;58(4):699-706. doi:10.1016/j.molcel.2015.04.021.

4. McGarrah RW, Crown SB, Zhang G-F, Shah SH, Newgard CB. Cardiovascular Metabolomics. Circ Res. 2018;122(9):1238-1258. doi:10.1161/CIRCRESAHA.117.311002.

5. Kraus WE, Muoio DM, Stevens R, et al. Metabolomic Quantitative Trait Loci (mQTL) Mapping Implicates the Ubiquitin Proteasome System in Cardiovascular Disease Pathogenesis. Lusis AJ, ed. PLOS Genet. 2015;11(11):e1005553. doi:10.1371/journal.pgen.1005553.

6. Yao C-H, Wang L, Stancliffe E, et al. Dose-Response Metabolomics To Understand Biochemical Mechanisms and Off-Target Drug Effects with the TOXcms Software. Anal Chem. 2020;92(2):1856-1864. doi:10.1021/acs.analchem.9b03811.

7.Huang X, Chen Y-J, Cho K, Nikolskiy I, Crawford PA, Patti GJ. X 13 CMS: Global Tracking of Isotopic Labels in Untargeted Metabolomics. Anal Chem. 2014;86(3):1632-1639. doi:10.1021/ac403384n.8. Lu D, Mulder H, Zhao P, et al. 13C NMR isotopomer analysis reveals a connection between pyruvate cycling and glucose-stimulated insulin secretion (GSIS). Proc Natl Acad Sci. 2002;99(5):2708-2713. doi:10.1073/pnas.052005699.

9. Warburg O, Wind F, Negelein E. The Metabolism Of Tumors in the body. J Gen Physiol. 1927;8(6):519-530. doi:10.1085/jgp.8.6.519.

Follow this link:
Diverse Opinions to Common Challenges in the Field of Metabolomics - Technology Networks

Costa Rica has the conditions to move towards the adoption of a personalized health care approach, despite some pending challenges in its objective of impacting the entire population.

A research report Personalized medicine in Latin America: Universalizing the promise of innovation, prepared by the Intelligence Unit of The Economist (EIU, for its acronym in English) indicated this and also highlighted that it is the Central American country with better social, political, economic and health conditions for its application.

To contribute to greater and better local coverage, the study recommends the construction of an initial frame of reference that includes issues of governance, awareness, and attitudes; infrastructure and financial management, where patients, the medical community, and health authorities understand the possibilities and challenges of personalized medicine in aspects such as patient and doctor education, improvements in digital and laboratory infrastructure, transition to advances in medicine, among others issues.

The study had the support of Roche Latin America and in addition to Costa Rica, it included Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Peru, and Uruguay. The nine countries were categorized as level one, two, or three, based on their assessment of the basic elements necessary for the successful implementation of personalized medicine, and where they are in the process.

The report places Costa Rica, Argentina, Brazil, Colombia, and Uruguay at level one, countries that it considers ready to decide, as it has substantial elements of the reference framework, but with important gaps in terms of its evaluation.

The best-prepared

At this level, Costa Rica is the Central American country best prepared to decide whether to create a comprehensive approach encompassing its entire health system and not just separate initiatives, which allows accompanying each patient on their journey, from prevention to treatment, monitoring and identifying their needs.

Follow this link:
Costa Rica is the Only country to advance in Personalized Medicine - The Costa Rica News

LONDON--(BUSINESS WIRE)--The RNA and DNA extraction kit market is poised to grow by USD 731.27 million during 2020-2024, decelerating at a CAGR of almost 9% during the forecast period.

For a More Detailed Analysis, Get a Free Sample Report Delivered in a Minute

The report on the RNA and DNA extraction kit market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.

The report offers an up-to-date analysis regarding the current global market scenario and the overall market environment. The market is driven by the increasing incidence of cancer.

The RNA and DNA extraction kit market analysis includes product and geography landscape. This study identifies the increasing adoption of personalized medicine as one of the prime reasons driving the RNA and DNA extraction kit market growth during the next few years.

This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.

The RNA and DNA extraction kit market covers the following areas:

RNA And DNA Extraction Kit Market Sizing

RNA And DNA Extraction Kit Market Forecast

RNA And DNA Extraction Kit Market Analysis

Develop Smart Strategies for Your Business: Get a Free Sample Report Now!

Companies Mentioned

Related Reports on Health Care Include:

Global DNA Sequencing Market - Global DNA sequencing market is segmented by solution (products and services) and geography (Asia, Europe, North America, and ROW). Click Here to Get an Exclusive Free Sample Report

Global Synthetic Biology Market - Global synthetic biology market is segmented by application (healthcare, industrial, food and agriculture, and others) and geography (Asia, Europe, North America, and ROW). Click Here to Get an Exclusive Free Sample Report

Key Topics Covered:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Product

Customer Landscape

Geographic Landscape

Vendor Landscape

Vendor Analysis

Appendix

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Subscribe to World-Class Market Intelligence and gain instant access to 17,000+ market research reports and connect with expert analysts

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Go here to see the original:
Global RNA and DNA Extraction Kit Market Growth Will Decelerate at a CAGR of Over 9%, 2020-2024 | However, Market Registers an Incremental Growth of $...

Today marks the start of RSNA 2020, the annual meeting of the Radiological Society of North America. I participated in my first RSNA 35 years ago and I am super excitedas I am every yearto reconnect with my radiology colleaguesand friendsand learnabout the latestmedical and scientific advances in our field. Of course, RSNA will be very different this year. Instead of traveling to Chicago to attend sessions and presentations, and wander the exhibits, Ill experience it all online. While I will miss the fun, excitement, and opportunities to connect that come with being there in person, I am amazed by what a rich and comprehensive conference the organizers of RSNA 2020 have put together using the advanced digital tools that we have at hand now.

It would be an understatement to say that this has been a year in which nearly everything is very different. From the tragic loss of life and rampant sickness to the economic disruption and the impact on our professions and our childrens education, so much of what we have been through because of COVID-19 has been extremely difficult. But the resilience of the response that so many people and institutions have shown in the face of all these challenges has been remarkable. And if it is possible to say there has been some good in all this, it would have to be the unprecedented transformation of the global healthcare ecosystem as hospitals, clinicians, and researchers have embraced a new generation of advanced digital health technologies that have helped them respond to the coronavirus crisis and laid the foundation for a more effective, affordable, and equitable future for healthcare.

As we move forward and the digital transformation of healthcare continues to accelerate, I see three significant trends that will influence the future of health and wellness.

One is the rapid emergence of virtual care through digital tools such as telehealth and remote monitoring that have made it safer and more convenient for patients to connect with their doctors during the pandemic, and that is empowering individuals to take charge of their health in entirely new ways. Virtual care has the capacity to personalize, accelerate, and augment treatment and prevention, saving time and money while improving outcomes. The ability to engage patients without requiring an in-person visit to a clinic will help ensure that they receive the right level of care and enable healthcare facilities to better manage the flow of patients into clinics and emergency rooms.

The second trend is the growing clarity of the promise of AI-driven precision medicine to serve as a major catalyst for improving health outcomes. As platforms for precision medicine and real-world evidence mature, well see exciting opportunities to improve treatment and prevention as we personalize patient care and transform how we diagnose infectious disease, cancer, and autoimmune disorders.

And, finally, where healthcare organizations have long been reluctant to move data offsite due to security, trust, and privacy concerns, we have seen a historic shift to the cloud over the last nine months. Now, driven by regulatory changes, the massive increase in medical data, and the critical need to access and analyze all that data by providers, payers, public health agencies, and researchers, its clear to everyone that moving to the cloud is both essential and hugely beneficial, both to providers and to patients.

As part of Microsofts ongoing commitment to help healthcare customers and partners continue to make progress toward recovery and build more resilient and effective systems of care, in late October we announced the general availability of Microsoft Cloud for Healthcare. This powerful industry-specific solution provides integrated capabilities for automated and efficient high-value workflows, and advanced data analysis functionally for structured and unstructured data so that healthcare organizations can truly transform information into insight and insight into action.

Built on the trusted capabilities of Microsoft 365, Microsoft Azure, Microsoft Dynamics 365, and Microsoft Power Platform, Microsoft Cloud for Healthcare is designed to enhance patient engagement to make it easier for patients to interact with caregivers, empower health team collaboration to facilitate more efficient and rich real-time communication and collaboration across the care continuum, and improve clinical and operational data insights with the ability of healthcare organizations to connect data from across their systems to predict risk and help improve patient care and operational efficiencies. Our robust partner ecosystem extends the power of Microsoft Cloud for Healthcare by building and extending advanced health solutions to meet the most demanding challenges in healthcare.

All of this makes it a particularly exciting time to be a radiologist. In many ways, our field has always been at the forefront of advances in the technologies that improve the movement, management, and analysis of large amounts of health data. This shouldnt really be a surprise, given that medical imaging accounts for nearly three-quarters of all health data, and analyzing 3D medical images can require up to 50 GB of bandwidth a day.

At Microsoft, streamlining the flow of health data, including medical imaging data, has been a significant focus of our work over the past few years. With the release of the Medical Imaging Server for DICOM (Digital Imaging and Communications in Medicine) in September, we offer developers powerful tools to ingest and persist medical imaging data in the cloud. Elevating interoperability, this is the first cloud technology to bring together DICOM data standard and FHIR (Fast Healthcare Interoperability Resources) which allows for persisting medical imaging metadata alongside other clinical data and sets the stage for multiple scenarios in research and diagnosis which may be too difficult or expensive to execute today.

Now, with Project InnerEye and the open-source InnerEye Deep Learning Toolkit, were making machine learning techniques available to developers, researchers, and partners that they can use to pioneer new approaches by training their own ML models, with the aim of augmenting clinician productivity, helping to improve patient outcomes, and refining our understanding of how medical imaging can be combined with other types of data to advance personalized medicine.

Learn more about our latest medical imaging offerings at the RSNA industry hour lunch and learn on December 3, 12:30 PM 1:30 PM Central Time.

Reimagining an industry that is as complex and touches as many lives as healthcare is a massive undertaking and at Microsoft, we have the privilege of working with amazing partners who stand at the forefront of innovation and progress in medical imaging technology.

Our partners are building transformative solutions to address some of the most difficult challenges in medical imaging. The amount of data generated by medical diagnostic imaging and connected devices is growing exponentially. Healthcare stakeholders, therefore, need effective ways of handling these data at scale.

This prompted Siemens Healthineers to build a dedicated cloud environment for Healthcare: The teamplay digital health platform. Through a certified gateway, the teamplay receiver, health data from connected medical devices can be aggregated. The teamplay cloud infrastructure is based on Azure, allowing secured processing of data within or outside a hospitals network.

GE Healthcares Centricity Universal Viewer Zero Footprint (ZFP) connects advanced diagnostic tools and system-wide image management platforms across the care continuum to help healthcare organizations improve diagnostic speed and confidence. ZFP users can now open Microsoft Teams with one click and share studies with other clinicians via the secure and compliant channels.1

SOPHiA GENETICS, the company pioneering the Data-Driven Medicine movementtrusted by over 1000 healthcare institutions in 85 countriesis highlighting their radiomics capabilities through the universal SOPHiA Platform for oncology and COVID CT imaging. Radiomics transforms standard medical imaging into mineable data assets that can be analyzed and combined with genomic data for improved decision support of precision medicine. SOPHiA Radiomics Solutions offer comprehensive workflows for multiple research and disease indication needs. SOPHiA multimodal platform is deployed on Microsoft Azure Cloud.

Microsoft and Sectra are partnering on cloud-based enterprise imaging and AI. In our joint RSNA webinar, Reap the benefits of enterprise imaging in the cloud with Microsoft & Sectra on December 3, we will introduce the brand new all-Azure and hybrid Microsoft Azure Stack offering as well as a demo of how Teams integration will help radiologists to cope in the new virtual world. We will hear Judy Bartlett from our joint customer John Muir share her experiences about moving from on-prem to running the Sectra Enterprise Imaging Solution as a Service on Azure.

With the imminent release of a new version of iConnect Enterprise Archive, IBM Watson Health will start to bring to market solutions that support a containerized deployment, in addition to VMWare, on both the IBM Cloud and Azure. The containerization of this portfolio is one of IBM Watson Healths key initiatives, starting with their VNA foundation and leveraging IBMs Red Hat OpenShift technology to ensure build once and deploy anywhere to be cloud native and agnostic.

With NVIDIA Clara Imaging, developers and researchers have the ability to accelerate data annotation, build domain-specialized AI models, and deploy intelligent imaging workflows with state-of-the-art pre-trained models and reference applications. Working closely with Azure, these innovators can jumpstart their development in the cloud and also address tough medical imaging challenges faster.During the current pandemic, our partnership is heavily accelerating progress Research in drug discovery (UC, Riverside; UCB Covid Moonshot) using GPUs on Azure for quantum mechanics model as well as using AI for SARS COVID-19 risk evaluation in Italy (Hospital San Raffaele, Milan). This partnership also enables the development and deployment of smart hospital solutions, running on NVIDIA Clara Guardian and Azure.

And finally,Flywheel is a cloud-scale informatics platform for biomedical research and collaboration. What is exciting about their differentiated work is the ability to securely leverage cloud at the edge with Microsoft Azure Stack Hub and transform these image analytics with Microsoft AI enabling tools and Flywheels depth in medical imaging data management and automated workflows.

Microsoft is the only cloud that extends to the edge from Microsoft Azure Edge Zone for 5G to Microsoft Azure Sphere for security. Were removing all barriers by covering all security and data sovereignty concerns in the cloud. With over 168,000 partners around the world, the network for innovation and collaboration runs deep. We cannot wait to see how together we will build solutions that transform healthcare around the world.

For more information on Microsoft Cloud for Healthcare, AI imaging tools, or to learn more about partnership visit the Microsoft virtual booth at RSNA or connect with us at our featured demo on November 29, 2:00 PM 2:30 PM Central Time.

[1] Technology in development that represents ongoing research and development efforts. These technologies are not products and may never become products. Not for sale. Not cleared or approved by the U.S. FDA or any other global regulator for commercial availability.

Go here to see the original:
Medical imaging, AI, and the cloud: what's next? - Microsoft Industry Blogs - Microsoft

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the cycling jersey market and it is poised to grow by USD 237.28 million during 2020-2024, progressing at a CAGR of over 8% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Click & Get Free sample report in minutes

Impact of COVID-19

The COVID-19 pandemic continues to transform the growth of various industries. However, the immediate impact of the outbreak is varied. While a few industries will register a drop in demand, numerous others will continue to remain unscathed and show promising growth opportunities. COVID-19 will have a low impact on the cycling jersey market. The market growth in 2020 is likely to increase compared to the market growth in 2019.

Frequently Asked Questions-

Related Reports on Consumer Discretionary Include:

Global Cycling Wear Market: The cycling wear market size has the potential to grow by USD 2.98 billion during 2020-2024, and the markets growth momentum will accelerate during the forecast period because of the steady increase in year-over-year growth. To get extensive research insights: Click and Get FREE Sample Report in Minutes!

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. ASSOS of Switzerland GmbH, adidas AG, FOX HEAD Inc., Giant Manufacturing Co. Ltd., Jaggad Pty Ltd., Pending System GmbH & Co. KG, Rapha Racing Ltd., Shimano Inc., Trek Bicycle Corp., and Troy Lee Designs Inc. are some of the major market participants. The growing need for fitness activities will offer immense growth opportunities. In a bid to help players strengthen their market foothold, this cycling jersey market forecast report provides a detailed analysis of the leading market vendors. The report also empowers industry honchos with information on the competitive landscape and insights into the different product offerings offered by various companies.

Technavio's custom research reports offer detailed insights on the impact of COVID-19 at an industry level, a regional level, and subsequent supply chain operations. This customized report will also help clients keep up with new product launches in direct & indirect COVID-19 related markets, upcoming vaccines and pipeline analysis, and significant developments in vendor operations and government regulations.

Cycling Jersey Market 2020-2024: Segmentation

Cycling Jersey Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR41655

Cycling Jersey Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. The cycling jersey market report covers the following areas:

This study identifies growing demand for personalized medicine as one of the prime reasons driving the cycling jersey market growth during the next few years.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Cycling Jersey Market 2020-2024: Key Highlights

Table of Contents:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Distribution channel

Customer Landscape

Geographic Landscape

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

More:
Cycling Jersey Market to grow by USD 237.28 million during 2020-2024, ASSOS of Switzerland GmbH and adidas AG Emerge as Key Contributors to Market...